SHANGHAI, Oct. 16, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has received the 2015 Asian CRO Company of the Year award from Frost & Sullivan, a leading business research and consulting firm. The award is part of the Frost & Sullivan Asia Pacific Best Practices Awards series, recognizing companies in Asia Pacific that demonstrate outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.
WuXi is being recognized for its strong performance and continued investments in the Asia Pacific region. Frost & Sullivan cited WuXi's local market knowledge, world-class facilities, reputation for high quality, rapid turnaround times, comprehensive customer support, and strong commitment to the highest global regulatory standards.
"We thank Frost & Sullivan for recognizing WuXi's diligent efforts in providing best-in-class service to our clients to help them accelerate healthcare product development with cost efficiency and quality," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "Combining our open-access enabling platform with local market expertise, we are working together with our customers and partners to bring better medicines faster to patients in Asia Pacific and around the world."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for investors)
Aaron Shi (for the media)
Director, Corporate Communications